
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is comparing having tiragolumab and atezolizumab with atezolizumab on its own for cervical cancer that has come back or spread.
Atezolizumab is an immunotherapy drug. It works by blocking a protein called PD-L1. By blocking PD-L1 atezolizumab could help the to find cancer cells and stop the growth of the cancer.
Doctors already use atezolizumab to treat some types of cancer that have the PD-L1 protein.
Tiragolumab is also an immunotherapy drug. It works by blocking a protein called TIGIT. By blocking TIGIT tiragolumab could also help the immune system recognise cancer cells and stop the growth of cancer.
We know that cervical cancer has the PD-L1 and TIGIT proteins. Researchers want to find out if atezolizumab on its own or atezolizumab with tiragolumab works for cervical cancer.
The main aims of this trial are to find:
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
Who can’t take part
Cancer related
You cannot join this trial if any of these apply. You:
Medical conditions
You cannot join this trial if any of these apply. You:
Other
You cannot join this trial if any of these apply. You:
This is an international phase 2 trial. The team need 160 women worldwide to take part with 12 women from the UK.
It is a randomised trial. You go into 1 of 2 treatment groups. Neither you nor your doctor chooses which group you go into. The 2 groups are:
Out of every 3 women who join, 2 go into the atezolizumab and tiragolumab group.
You have atezolizumab and tiragolumab as a drip into a vein. You have it every 3 weeks.
You have atezolizumab on its own as a drip into a vein. You have it every 3 weeks.
You continue with treatment as long as it is helping and the side effects aren’t too bad.
Research samples
You give blood samples and tissue samples (biopsies) before starting treatment and during treatment. Researchers use these to look for substances () that might tell them how well the treatment is working and to find out more about cervical cancer.
You see the doctor to have tests before joining the trial. These tests include:
During treatment you see the doctor every 3 weeks. This is for bloods and to see how you are doing.
You have a CT scan or MRI scan every 6 weeks for 48 weeks.
You see the doctor within a month of finishing treatment for blood tests. You then see them every 3 months until the study ends.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Atezolizumab and tiragolumab can affect the immune system. They may cause inflammation in different parts of the body which can cause serious side effects. This could happen during treatment, or some months after treatment has finished. Rarely, these side effects could be life threatening.
If you have any of these side effects, you should tell the doctor or nurse as soon as possible that you are on or have been on an immunotherapy.
Tiragolumab is a new drug and there might be side effects we don’t know about yet. We do know that some people have a reaction while having tiragolumab. The symptoms can be:
Tell your nurse or doctor straight away if you have any of these symptoms when having tiragolumab. They will slow down or possibly stop the drip. Your doctor might prescribe some medication to have before your next tiragolumab to prevent or reduce these symptoms.
We have information about atezolizumab and its side effects.
Your doctor or a member of the trial team will talk to you about the side effects of atezolizumab and tiragolumab before you agree to join the trial.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Mary McCormack
Roche
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”